The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity.
A. Garcia
No relevant relationships to disclose
A. Awada
No relevant relationships to disclose
S. Chan
No relevant relationships to disclose
G. H. M. Jerusalem
No relevant relationships to disclose
R. E. Coleman
No relevant relationships to disclose
M. T. Huizing
No relevant relationships to disclose
A. Mehdi
No relevant relationships to disclose
S. M. O'Reilly
No relevant relationships to disclose
J. T. Hamm
No relevant relationships to disclose
P. J. Barrett-Lee
No relevant relationships to disclose
V. Cocquyt
No relevant relationships to disclose
K. Sideras
No relevant relationships to disclose
D. E. Young
No relevant relationships to disclose
M. Brown
Employment or Leadership Position - Nektar
C. Zhao
Employment or Leadership Position - Nektar
A. L. Hannah
Consultant or Advisory Role - Nektar
A. C. F. Leung
Employment or Leadership Position - Nektar
L. K. Masuoka
Employment or Leadership Position - Nektar
E. A. Perez
No relevant relationships to disclose